Načítá se...
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
BACKGROUND: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. METHODS: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatm...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5975605/ https://ncbi.nlm.nih.gov/pubmed/29872317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S151276 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|